ALGS Aligos Therapeutics

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

Aligos Therapeutics To Present at the Piper Sandler Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, and the Aligos management team, will present at the 2023 Piper Sandler Healthcare Conference being held in New York on Thursday, November 30, 2023 at 12:30 p.m. ET.

Piper Sandler Healthcare Conference Information:

 Date Thursday, November 30, 2023  
 Time: 12:30 p.m. ET  
 Presenter: Lawrence Blatt, Ph.D., MBA, CEO of Aligos  
 Webcast: Link  

A replay of the session will be available following the conference for 90-days through the Aligos investor section of the website .

The Aligos management team will also participate in investor 1x1 meetings during the conference. Please contact your Piper Sandler representative to schedule one-on-one meetings with Aligos during the conference.

About Aligos

Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of liver and viral diseases. Aligos’ strategy is to harness the deep expertise and decades of drug development experience its team has in liver and viral diseases to discover and develop potentially best in class therapeutics for nonalcoholic steatohepatitis (NASH) and viruses with high unmet medical need such as coronaviruses and chronic hepatitis B (CHB).

Media Contact

Veronica Eames

LifeSci Communications

Investor Contact

Corey Davis, Ph.D.

LifeSci Advisors





EN
20/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aligos Therapeutics

 PRESS RELEASE

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 14,100 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on Dec...

 PRESS RELEASE

Aligos Therapeutics Presents Positive Data at HEP-DART 2025

Aligos Therapeutics Presents Positive Data at HEP-DART 2025 Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from four presentations, including two oral presentations, at the HEP-DART 2025 Meeting, being held December 7 – ...

 PRESS RELEASE

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing R...

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SOUTH SAN FRANCISCO, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 23,600 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on Nov...

 PRESS RELEASE

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025

Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025 Oral presentation of 96-week treatment and post-treatment data suggest best-in-class potential of pevifoscorvir sodium SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced positive data from eight presentations, including one oral presentation, at the American Association for the Study of Liver Disease’s (AASLD...

 PRESS RELEASE

Aligos Therapeutics Reports Recent Business Progress and Third Quarter...

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2025. “Our Phase 2 B-SUPREME study of pevifoscorvir sodium (pevy) is enrolling nicely, with subjects dosed across a number of countries, including the U.S., China...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch